Exabis Library
Welcome to the e-CCO Library!
P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P581: Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P581: Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P582: Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P582: Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P582: Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P583: Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P583: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on adalimumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P583: Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P583: Tofacitinib for acute severe ulcerative colitis: a systematic review
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P583: Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P584: Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM